NLOC-015A, a novel multi-target small molecule, has ADMET PK properties of a good drug-like candidate and efficiently suppressed the proliferation and oncogenic phenotypes of NSCLC with concomitant inhibition of EGFR, mTOR, Akt, NF-κB, YAP1, MEK signaling network. This evidence concerns the gene EGFR and non-small cell lung carcinoma.